Market Research Report
Asia Pacific Opioids Drug Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||757036|
|Published||Content info||77 Pages
Delivery time: 2-3 business days
|Asia Pacific Opioids Drug Market Forecast 2019-2027|
|Published: December 17, 2018||Content info: 77 Pages||
The regional market for opioid drugs in the Asia-Pacific is rapidly growing at 3.06% CAGR during the forecast period 2019-2027, where it was valued $XX million in its base year of 2018. The rising awareness about palliative care that is necessary for patients suffering from incurable diseases is expected to drive the market growth in this region. China, India, Japan, Australia, South Korea & Rest of Asia Pacific are deliberated for this study.
The sale of sustained-release formulations of opioid drugs and other forms of opioid-dependent pain relief medications are expected to pave more ways for the market growth. Also, the reduction in the use of non-addictive pain relievers is going to enhance the use of addiction-deterrent variants of opioid drugs in the upcoming years. Japan owns the largest shares of the Asia Pacific opioid drugs market, mainly because of the higher frequency of chronic and severe pain, although the market growth can get obstructed due to the strict and restrictive laws for its prescriptions and the stigma associated with opioid addiction.
Hikma Pharmaceuticals PLC, Acura Pharmaceuticals, Inc., Lannett Co. Inc., BioDelivery Sciences International, Inc., Sun Pharmaceutical Industries Limited (Sun Pharma), Cipher Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Allergan PLC, Egalet Corp., Indivior, Inc., Insys Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Lupin Ltd., Mylan NV, Pfizer, Inc., Purdue Pharma LP, Sanofi-Aventis S.A. and Teva Pharmaceutical Industries Ltd. are the predominant revenue reapers for the Asia-Pacific opioid drugs market.